Die neue Generation der Anti-VEGF-Wirkstoffe: Sind sie wirklich besser?

Bevor die im Titel gestellt Frage detailliert beantwortet werden kann, muss zunächst definiert werden, aus welcher Perspektive sie betrachtet werden soll und was „besser“ bedeutet.

Publikationsverlauf

Artikel online veröffentlicht:
16. Januar 2025

• Literatur

• 1 Brown DM, Boyer DS, Do DV. et al. Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2/3 trial. Lancet 2024; 403: 1153-1163
• 2 Dugel PU, Singh RP, Koh A. et al. HAWK and HARRIER: Ninety-Six-Week Outcomes from the Phase 3 Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration. Ophthalmology 2021; 128: 89-99
• 3 Heier JS, Boyer D, Nguyen QD. et al. The 1-year results of CLEAR-IT 2, a phase 2 study of vascular endothelial growth factor trap-eye dosed as-needed after 12-week fixed dosing. Ophthalmology 2011; 118: 1098-1106
• 4 Heier JS, Khanani AM, Quezada Ruiz C. et al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet 2022; 399: 729-740
• 5 Lanzetta P, Korobelnik JF, Heier JS. et al. Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial. Lancet 2024; 403: 1141-1152
• 6 Monés J, Srivastava SK, Jaffe GJ. et al. Risk of Inflammation, Retinal Vasculitis, and Retinal Occlusion-Related Events with Brolucizumab: Post Hoc Review of HAWK and HARRIER. Ophthalmology 2021; 128: 1050-1059
• 7 Singh RP, Barakat MR, Ip MS. et al. Efficacy and Safety of Brolucizumab for Diabetic Macular Edema: The KINGFISHER Randomized Clinical Trial. JAMA Ophthalmol 2023; 141: 1152-1160
• 8 Wong TY, Haskova Z, Asik K. et al. Faricimab Treat-and-Extend for Diabetic Macular Edema: 2-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials. Ophthalmology 2024; 131: 708-723
• 9 Wykoff CC, Abreu F, Adamis AP. et al. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials. Lancet 2022; 399: 741-755